Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00003343 | Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer | PHASE3 | COMPLETED | 525 | — | — | Mar 1, 1998 | - | Aug 8, 2012 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| endocrine-modulating drug therapy | DRUG | - |
| mitoxantrone hydrochloride | DRUG | - |
| prednisone | DRUG | - |
| prinomastat | DRUG | - |
DISEASE CHARACTERISTICS: Histologically confirmed metastatic, hormone refractory prostate cancer Must have undergone prior orchiectomy or treatment with an LHRH analog Prior treatment with an antiandrogen agent (e.g., flutamide or bicalutamide) is optional Castrate serum testosterone no greater than...